FCX vs TBPH · P/E 38, rev $25.45B vs P/E 7.5, rev $18.8M
Freeport-McMoran Copper & Gold Inc (FCX) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported FCX revenue for 2024-12-31 was $25.45B. Net income was $4.40B. Revenue was up 11.4% from 2023-12-31 to 2024-12-31. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported TBPH revenue for 2024-12-31 was $18.8M. Net income was -$15.5M. Revenue was up 11.2% from 2024-09-30 to 2024-12-31. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the FCX and TBPH stock pages for the full models.
Not investment advice.